Company intelligence / Profile preview

AccelBio

New York City, New York, United Statesaccelbio.com ↗

Ownership: Private
Employees: ~2
Development stage: Commercial

Overview

AccelBio offers robotic cell-based assays and custom molecular solutions for drug discovery and diagnostics. The company specializes in high-throughput screening using unique chemical entities, with expertise in RNA biology and neurobiology. It has developed rapid viral RNA diagnostic platforms for COVID‑19 detection globally. No clinical trial results are reported as the company is primarily a service provider rather than a therapeutic developer.

Therapeutic areas: Infectious DiseasesNeurologyHematology
Modalities: RNA therapySmall moleculeBiologic (cell-based assays, diagnostic platforms)
Industry: Molecular Diagnostics

Partnerships

Not publicly disclosed; works with biotech/pharma companies and academic labs

Beyond the preview

Go deeper on AccelBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccelBio.

Explore the full profile